The Chinese antibody-drug conjugate specialist Duality Biologics (DualityBio), together with partner BioNTech SE, are racing against a narrowing window of opportunity to exploit the HER2-low breast cancer field, which was first kicked into high gear by Daiichi Sankyo Co., Ltd. and AstraZeneca PLC’s ADC Enhertu (trastuzumab deruxtecan).
Key Takeaways
-
DualityBio and BioNTech will initiate the US-only Phase III DYNASTY-Breast02 of their HER2-targeting ADC DB-1303 in chemotherapy-naive patients with HER2-low and HR-positive breast cancer.
- ...
The Sino-German alliance is planning to initiate the US-only Phase III DYNASTY-Breast02 trial with its HER2-targeting ADC DB-1303 in chemotherapy-naive patients with HER2-low and HR-positive breast cancer in the second-line...